AbbVie Inc. Capex/Depreciation

Capex/Depreciation of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex/Depreciation growth rates and interactive chart.

Highlights and Quick Summary

  • Capex/Depreciation for the quarter ending September 29, 2021 was -0.1 (a 15.12% increase compared to previous quarter)
  • Year-over-year quarterly Capex/Depreciation decreased by -24.5%
  • Annual Capex/Depreciation for 2020 was -0.12 (a -54.95% decrease from previous year)
  • Annual Capex/Depreciation for 2019 was -0.27 (a -24.29% decrease from previous year)
  • Annual Capex/Depreciation for 2018 was -0.36 (a 2.58% increase from previous year)
  • Twelve month Capex/Depreciation ending September 29, 2021 was -0.1 (a 1.9% increase compared to previous quarter)
  • Twelve month trailing Capex/Depreciation decreased by -17.19% year-over-year
Trailing Capex/Depreciation for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-0.1 -0.1 -0.11 -0.12
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex/Depreciation of AbbVie Inc.

Most recent Capex/Depreciationof ABBV including historical data for past 10 years.

Interactive Chart of Capex/Depreciation of AbbVie Inc.

AbbVie Inc. Capex/Depreciation for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.1 -0.09 -0.08
2020 -0.14 -0.09 -0.11 -0.22 -0.12
2019 -0.32 -0.31 -0.26 -0.21 -0.27
2018 -0.28 -0.65 -0.26 -0.27 -0.36
2017 -0.49 -0.33 -0.33 -0.25 -0.35
2016 -0.35 -0.37 -0.45 -0.45 -0.4
2015 -0.56 -0.56 -0.61 -0.92 -0.64
2014 -0.79 -0.94 -0.7 -0.69 -0.78
2013 -0.76 -0.57 -0.5 -0.39 -0.55
2012 -0.31 0.08 -0.32 -0.51 -0.29
2011 -0.32 -0.2 -0.29 -0.31 -0.28

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.